Basic Information
| LncRNA/CircRNA Name | TP73-AS1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | ENSG00000227372 |
| Refseq | NR_033708 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | qPCR, Western blot, Luciferase reporter assay, etc. |
| Sample | primary pancreatic cancer, pancreatic duct epithelial cell line HPDE6-C7 and human pancreatic cancer cell lines SW1990, CAPAN-1, JF305, PANC-1, and BxPC-3 |
| Expression Pattern | up-regulated |
| Function Description | TP73-AS1 was up-regulated in pancreatic cancer tissue and cell lines. High levels of TP73-AS1 were correlated with poor clinicopathological characteristics and shorter overall survival. MiR-141 was a direct target for TP73-AS1, while BDH2 was a direct target for miR-141. The knockdown of TP73-AS1 significantly inhibited the migration and invasion of pancreatic cancer cells, while the miR-141 inhibitor significantly restored the migration and invasion. Therefore, TP73-AS1 positively regulated BDH2 expression by sponging miR-141. These findings suggest that TP73-AS1 serves as an oncogene and promotes the metastasis of pancreatic cancer.Moreover, TP73-AS1 could serve as a predictor and a potential drug biotarget for pancreatic cancer. |
| Pubmed ID | 30643007 |
| Year | 2019 |
| Title | LncRNA TP73-AS1 sponges miR-141-3p to promote the migration and invasion of pancreatic cancer cells through the up-regulation of BDH2 |
External Links
| Links for TP73-AS1 | GenBank HGNC NONCODE |
| Links for pancreatic cancer | OMIM COSMIC |